The mechanisms by which EGFR inhibitors induce IKK/NF-κB are complicated.17–20 It has been reported, both here and previously, that HER2 plays an important role in EGFR inhibitor resistance, and that EGFR inhibitors upregulate HER2 and HER3.18,28,31,32 Therefore, we treated HNSCC with the dual EGFR/HER2 inhibitor, Lapatinib. Here, ERBB2 is linked to head and neck squamous cell carcinoma.